• Markets
    • icon
  • Companies
NSB · ASX

Neuroscientific Biopharmaceuticals Ltd. (ASX:NSB)

AU$0.05

 0.0 (0.0%)
ASX:Live
06/12/2023 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NSB Overview

NSB Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About NSB

Website

Neuroscientific Biopharmaceuticals Ltd.

Telephone

N/A

Address

Description

N/A

NSB Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.17

Trade Value (12mth)

AU$1,666.00

1 week

-29.58%

1 month

-16.67%

YTD

-58.33%

1 year

-68.75%

All time high

0.54

Key Fundamentals

EPS 3 yr Growth

-79.800%

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-45.10%

ROIC

-20.90%

Interest Coverage

N/A

Quick Ratio

8.40

Other Data

Shares on Issue (Fully Dilluted)

143m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

NSB Announcements

Latest Announcements

Date Announcements

31 October 23

Investor Update Presentation

×

Investor Update Presentation

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Appointment of CEO

×

Appointment of CEO

30 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 October 23

Investor Update Webinar

×

Investor Update Webinar

30 October 20

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 October 18

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 November 23

Chair's address to shareholders & AGM presentation

×

Chair's address to shareholders & AGM presentation

30 November 23

Results of Meeting

×

Results of Meeting

30 June 22

First Subject Recruited for Early-Phase Clinical Trial

×

First Subject Recruited for Early-Phase Clinical Trial

30 August 23

Corporate Governance Statement

×

Corporate Governance Statement

30 August 23

Appendix 4G

×

Appendix 4G

30 August 22

2022 Annual Report and Appendix 4E

×

2022 Annual Report and Appendix 4E

30 August 22

NeuroScientific releases FY2022 Results

×

NeuroScientific releases FY2022 Results

30 August 22

Appendix 4G

×

Appendix 4G

30 August 22

Corporate Governance Statement

×

Corporate Governance Statement

30 August 19

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

29 October 19

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 October 18

Annual Report to shareholders

×

Annual Report to shareholders

29 July 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 September 23

Date of AGM & Closing Date for Director Nominations

×

Date of AGM & Closing Date for Director Nominations

28 October 20

AusBiotech Invest 2020 Conference Presentation

×

AusBiotech Invest 2020 Conference Presentation

28 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 February 23

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

28 February 22

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

NSB Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.07 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.07 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.3 -227.5 89.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.06 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.05 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.2 -262.1 91.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.5 -26.9 -20.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.04 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.10 0.04 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 141.0 -63.5 -14.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 143 143 143 Lock Lock Lock
Basic m Lock Lock Lock Lock 143 143 143 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 10 6 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.4 -5.7 10.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -10 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.3 -150.8 41.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -11 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -43.6 -148.7 41.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -10 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -10 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 -228.4 89.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -7 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 14 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -7 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.2 -164.0 66.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 14 7 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 15 8 5 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -14 -7 -5 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 15 6 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 15 6 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 300.2 -62.2 -15.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.4 -134.9 -20.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.3 -104.4 -119.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -34.8 -103.7 -20.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -28.5 -69.0 -45.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.4 0.7 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -97.0 -130.7 -104.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 64.6 3.3 8.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 64.6 3.3 8.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 97.5 98.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,164.5 -313.0 -385.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.4 -134.9 -20.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.4 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 705.3 6,588.4 8,669.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -705.3 -6,588.4 -8,669.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NSB Shortsell

Frequently Asked Questions

The current share price of Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is AU$0.05.
The 52-week high share price for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is AU$0.17.
The 52-week low share price for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX)? is AU$0.04.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not pay a dividend.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not pay a dividend.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not offer franking credits.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is classified in the Healthcare.
The current P/E ratio for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.